High Blood Pressure, the Silent Killer: How Can We Do better in Wales?

Slides:

Advertisements

Similar presentations

BY Dr. Khaled Helmy Al Mahmora Chest Hospital BY Dr. Khaled Helmy Al Mahmora Chest Hospital Treatment Of Hypertension In Diabetes.

Advertisements

Valsartan Antihypertensive Long-Term Use Evaluation Results

Modelling the impact of service innovation in Stroke Care Tanaka Business School: Imperial College. Lead researcher: Dr Benita Cox Background Stroke is.

Overview of the CVD Risk Reduction Demonstration Project Kelly Acton, MD, MPH, FACP IHS Division of Diabetes Treatment & Prevention.

The United States & Heart Disease Presented today by; Matt Lorup, Keith Arline, & Nick Knight.

Hypertension By Dr. Nagwa Eid Saad Prof. Of Internal Medicine & Family Medicine In Cairo University.

Hypertension Guideline

HYPERTENSION The Alabama Department of Public Health’s Hypertension Program.

William B. Kannel, MD, FACC Former Director, Framingham Heart Study

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

Circulatory System- Hypertension Disease By: Jennifer Arroyo.

EXAM 1.A normal adult should have their BP checked at least how often? 2.What level of CVD risk over 10 years is considered high risk for primary prevention?

1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.

Northern England Strategic Clinical Network Conference 15 th May 2015.

1 EFFECT STUDY 2 EFFECT STUDY  Set national cardiac care benchmarks for hospitals to work towards 

Chronic Care Management Hypertension Results: Represents Health Disparities Collaborative for Hypertension Overall CAP Results.

By Katie, Jenny & Tawan. Intro Hypertension is a chronic medical heart condition that is most likely to be heredity High Blood pressure is cause by high.

High Blood Pressure The Silent Killer people worldwide die yearly people worldwide die yearly.

NICE CG127: Implementation in Primary care Dr Terry McCormack, Whitby.

Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

Salt, Heart Disease, and Stroke Norm Campbell. 1) The role of increased blood pressure as a determinant of adverse outcomes 2) The health risks of high.

ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.

UKHDS (UKPDS): UK Hypertension in Diabetes Study Purpose To determine whether tight control of blood pressure (aiming for BP

TECHNOLOGY IN THE MEDICAL FIELD: FOCUSING ON CARDIOVASCULAR DISEASE Lea Anne Cape Dr. Guenzel ENC March 26, 2014.

Prevalence and management of cardiovascular risks in renal transplant recipients Dr VS Aithal Consultant Nephrologist Swansea.

December 02 1 Vascular mortality: Age-specific hazard ratios for 20 mmHg lower usual SBP deaths at ages

Do Now: 1. What is high blood pressure? 2. List three way to reduce high blood pressure. 3. Why is having high blood pressure a concern?

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.

From: Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study Ann Intern Med. 2015;163(5):

Evidence based medicine Antihypertensive drugs in the elderly Group 1 and 6 -Heba Othman -Heba Sabry -Reem Ahmed -Dina Reda -Dalia El Magraby.

HIGH BLOOD PRESSURE The Silent Killer

Antonio Coca, MD, PhD, FRCP, FESC

Dr John Cox Diabetes in Primary Care Conference Cork

Lambeth Diabetes update

Nephrology Journal Club The SPRINT Trial Parker Gregg

a cautionary note from SPRINT

a cautionary note from SPRINT

Tackling High Blood Pressure Through Community Pharmacy

Hypertension November 2016

Mortality and harm Learning Set. National context update

Impact and costing of cardiovascular disease treatmentin Kwara State Health Insurance (KSHI) program. University of Ilorin Teaching Hospital (UITH) Amsterdam.

Copyright © 2007 American Medical Association. All rights reserved.

The Anglo Scandinavian Cardiac Outcomes Trial

PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,

B – The Cardiovascular System

High Blood Pressure (Hypertension)

فشارخون بالا را جدی بگیرید

Fiona Caplan-Dean Pharmacy Services Development Manager UK

Teaching Tool: Blood Pressure Classification

Do Now: What is high blood pressure?

Systolic Blood Pressure Intervention Trial (SPRINT)

Improving outcomes for CVD

Blood Pressure Fit and Healthy.

Section VIII. Ambulatory BP Measurement

Managing Hard-To-Treat Hypertension: What Every Physician Should Know

Hypertension Guidelines

CVD Secondary Prevention plans within Thames Valley

The Hypertension in the Very Elderly Trial (HYVET)

Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Helen O’Kelly Health service engagement lead, south east

Lambeth Diabetes update

Hypertension November 2016

CVD Secondary Prevention plans within Thames Valley

Prevalence and costs of treating uncomplicated stage 1 hypertension in primary care: a cross-sectional analysis by James P Sheppard, Kate Fletcher, Richard.

The Heart Truth Delaware Background

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.

Presentation transcript:

High Blood Pressure, the Silent Killer: How Can We Do better in Wales? MediWales Connects Conference High Blood Pressure, the Silent Killer: How Can We Do better in Wales? 2nd July 2019

The Size of the Problem within Wales

but…

In total across Wales…

Across Wales, the numbers of people with hypertension treated to target are falling… Source: BHF analysis of QOF data 2017/18 (150/90 target)

Treatment for high BP significantly reduces the risk of heart attack, stroke, heart failure and all- cause mortality Every 10mmHg reduction in systolic BP reduces the risk of major Cardiovascular events by 20% Treatment is very effective at lowering BP and improving outcomes

High Blood Pressure, The Silent Killer Wales Atlas of Variation, how data can support improving cardiovascular care: Dr Jonathan Goodfellow, National Clinical Lead, Wales Cardiac Network Innovative approaches to community Blood Pressure programmes: The learning from BHF funded programmes: Rhiannon Edwards, BHF CVD Clinical Development Coordinator for Wales. May Measurement Month Campaign: Dr Barry McDonnell, Reader in Cardiovascular Physiology, Cardiff Metropolitan University 5 mins for questions.